NanoViricides Highlights Need for Broad-Spectrum Antivirals Post-Hantavirus Incident

In a recent statement, NanoViricides, Inc. stressed the importance of broad-spectrum antiviral drugs like NV-387, following the Andes hantavirus outbreak on the MV Hondius cruise ship. Efforts to contain the virus included quarantining the ship and tracing passenger contacts to prevent a potential epidemic.

Anil R. Diwan, President of NanoViricides, noted that NV-387 had shown efficacy against lethal lung infections in animal models, suggesting its potential utility under emergency procedures. NV-387 has completed Phase I trials for safety in humans.

The virus, affecting passengers' lungs, underscored the need for antivirals as global travel makes rapid viral spread possible. NanoViricides claims that up to 90% of viral infections can be addressed by NV-387, reinforcing its role in preventing epidemics.